Event-based analysis of visual field change can miss fast glaucoma progression detected by a combined structure and function index
- 31 Downloads
To investigate the relationship between progression assessed by the visual field guided progression analysis (GPA) and rates of structural and functional change in glaucoma eyes.
This was a longitudinal observational study of 135 eyes of 97 patients with glaucoma followed for an average of 3.5 ± 0.9 years. All patients had standard automated perimetry (SAP) and retinal nerve fiber layer (RNFL) analysis with spectral domain optical coherence tomography (SDOCT), with an average of 6.8 ± 2.3 visits. A control group of healthy eyes followed longitudinally was used to estimate age-related change. Visual field progression was assessed using the Humphrey Field Analyzer GPA. Estimates of retinal ganglion cell counts from SAP and SDOCT were used to obtain a combined index of glaucomatous damage (RGC index) according to a previously described algorithm. Progression by SDOCT and the retinal ganglion cell (RGC) index were defined as statistically significant (P < 0.05) slopes of change that were also faster than age-related change estimated from healthy eyes.
From the 135 eyes, 15 (11%) progressed by GPA, 21 (16%) progressed by SDOCT, and 31 (23%) progressed by the RGC index. Twenty-one eyes showed progression by the RGC index that was missed by the GPA. These eyes had an average rate of change in estimated RGC counts of − 28,910 cells/year, ranging from two to nine times faster than expected age-related losses.
Many glaucomatous eyes that are not found to be progressing by GPA may actually have fast rates of change as detected by a combined index of structure and function.
KeywordsOptical coherence tomography Visual field Combined structure function index Glaucoma progression
Compliance with ethical standards
Conflict of interest
The authors have made the following disclosures: C.Z.—none; A.J.T.—research support from Heidelberg Engineering; F.B.D.—none; A.A.J.—none; F.A.M.—F: Alcon Laboratories, Bausch & Lomb, Carl Zeiss Meditec, Heidelberg Engineering, Merck, Allergan, Sensimed, Topcon, Reichert, National Eye Institute, R: Alcon Laboratories, Allergan, Carl Zeiss Meditec, Reichert, C: Allergan, Carl Zeiss Meditec, Novartis.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional review board and human subjects committee of the Duke University and University of California San Diego (UCSD) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- 8.Medeiros FA, Zangwill LM, Bowd C, Mansouri K, Weinreb RN (2012) The structure and function relationship in glaucoma: implications for detection of progression and measurement of rates of change. Invest Ophthalmol Vis Sci 53(11):6939–6946. https://doi.org/10.1167/iovs.12-10345 CrossRefPubMedPubMedCentralGoogle Scholar
- 10.Zhang C, Tatham AJ, Weinreb RN, Zangwill LM, Yang Z, Zhang JZ, Medeiros FA (2014) Relationship between ganglion cell layer thickness and estimated retinal ganglion cell counts in the glaucomatous macula. Ophthalmology 121(12):2371–2379. https://doi.org/10.1016/j.ophtha.2014.06.047 CrossRefPubMedPubMedCentralGoogle Scholar
- 15.Meira-Freitas D, Lisboa R, Tatham A, Zangwill LM, Weinreb RN, Girkin CA, Liebmann JM, Medeiros FA (2013) Predicting progression in glaucoma suspects with longitudinal estimates of retinal ganglion cell counts. Invest Ophthalmol Vis Sci 54(6):4174–4183. https://doi.org/10.1167/iovs.12-11301 CrossRefPubMedPubMedCentralGoogle Scholar
- 18.Leung CK, Cheung CY, Weinreb RN, Qiu K, Liu S, Li H, Xu G, Fan N, Pang CP, Tse KK, Lam DS (2010) Evaluation of retinal nerve fiber layer progression in glaucoma: a study on optical coherence tomography guided progression analysis. Invest Ophthalmol Vis Sci 51(1):217–222. https://doi.org/10.1167/iovs.09-3468 CrossRefPubMedGoogle Scholar